Israeli biotech company BiondVax Pharmaceuticals, which went public in 2015, has undergone significant changes, including a shift in focus and the appointment of a new CEO in 2021. As part of its transformation, the company is rebranding with a new name.BiondVax is now Scinai Immunotherapeutics. While its roots were initially in the pursuit of a universal flu vaccine, the company has shifted its focus in R&D.

以色列生物技术公司BiondVax Pharmaceuticals于2015年上市，经历了重大变化，包括焦点转移和2021年任命新首席执行官。作为转型的一部分，该公司正在更名。BiondVax现在是Scinai Immunotherapeutics。虽然其根源最初是追求通用流感疫苗，但该公司已将重点转移到研发领域。

Now, its endeavors include early-stage development of an inhaled COVID-19 therapy, a strategic autoimmune partnership with Max Planck Innovation and the establishment of a new CDMO business. That unit has also been renamed under the banner Scinai Bioservices and will be a strong core of the company.The new corporate name is the biotech’s “latest step to better reflect its fresh start and new direction,” according to a press release. But it may prove a tough rebirth for the company.

现在，其努力包括吸入COVID-19疗法的早期开发，与Max Planck Innovation的战略自身免疫合作伙伴关系以及建立新的CDMO业务。该单位也已在Scinai Bioservices旗帜下更名，并将成为该公司的强大核心。据新闻稿称，新公司名称是生物技术公司的“更好地反映其新开端和新方向的最新步骤”。但这可能对公司来说是一个艰难的复兴。

It has recently come to light that it does not comply with Nasdaq listing rules, as the stock exchange issued a deficiency letter stating that it fails to meet the minimum stockholders’ equity requirements to maintain its listing.Scinai Bioservices has until October to sort this out, with part of the plan to get there being to leverage that new CDMO as well as going through with a “cost-savings plan,” as set out in its recent financial results.“We are incredibly optimistic about Scinai’s growth potential and ability to deliver value to our stakeholders,” said CEO Amir Reichman in a statement.“The biotech sector has been through an extremely challenging time in the past 18-24 months, with low stock prices and scarce capital.

最近发现它不符合纳斯达克的上市规则，因为证券交易所发布了一封缺陷信，声明它未能满足股东的最低股权要求以保持其上市。Scinai Bioservices直到10月才对其进行整理，部分计划是利用新的CDMO以及最近的财务结果中规定的“成本节约计划”。首席执行官Amir Reichman在一份声明中说：“我们对Scinai的增长潜力和向利益相关者提供价值的能力非常乐观。“在过去的18-24个月中，生物技术部门经历了一个极具挑战性的时期，股票价格低廉，资本稀缺。

We have nevertheless made tremendous progress executing our turnaround program with limited resources and believe we are at the cusp of building a significant and suc.

尽管如此，我们在资源有限的情况下执行周转计划取得了巨大进展，并相信我们正处于建立重大成功的尖端。